Prospective analysis of the impact of <i>VEGF‐A</i> gene polymorphisms on the pharmacodynamics of bevacizumab‐based therapy in metastatic breast cancer patients

Abstract

The role for VEGF-A 936C > T polymorphism as a potential marker of TTP in breast cancer patients receiving bevacizumab-containing therapy concords with the known impact of VEGF-A 936C > T polymorphism on VEGF-A expression.